These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21953502)

  • 21. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab.
    Cézé N; Ternant D; Piller F; Degenne D; Azzopardi N; Dorval E; Watier H; Lecomte T; Paintaud G
    Ther Drug Monit; 2009 Oct; 31(5):597-601. PubMed ID: 19730278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study.
    Grisic AM; Khandelwal A; Bertolino M; Huisinga W; Girard P; Kloft C
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):628-638. PubMed ID: 33015996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab.
    Fontana E; Pucci F; Ardizzoni A
    Anticancer Drugs; 2014 Jan; 25(1):120-2. PubMed ID: 24025565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?].
    Soussan-Dahan M; Lapeyre-Mestre M; Bondon-Guitton E; Delord JP; Despas F
    Therapie; 2014; 69(6):499-507. PubMed ID: 25269144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
    Wang E; Kang D; Bae KS; Marshall MA; Pavlov D; Parivar K
    J Clin Pharmacol; 2014 Oct; 54(10):1108-16. PubMed ID: 24737343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
    Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
    Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-linear pharmacokinetics of high-dose intravenous verapamil.
    Toffoli G; Robieux I; Fantin D; Gigante M; Frustaci S; Nicolosi GL; De Cicco M; Boiocchi M
    Br J Clin Pharmacol; 1997 Sep; 44(3):255-60. PubMed ID: 9296319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.
    Glimelius B; Lahn M; Gawande S; Cleverly A; Darstein C; Musib L; Liu Y; Spindler KL; Frödin JE; Berglund A; Byström P; Qvortrup C; Jakobsen A; Pfeiffer P
    Ann Oncol; 2010 May; 21(5):1020-6. PubMed ID: 19901015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.
    Port RE; Schlemmer HP; Bachert P
    Eur J Clin Pharmacol; 1994; 47(2):187-93. PubMed ID: 7859808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
    Kloft C; Graefe EU; Tanswell P; Scott AM; Hofheinz R; Amelsberg A; Karlsson MO
    Invest New Drugs; 2004 Jan; 22(1):39-52. PubMed ID: 14707493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
    Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of kahalalide F in advanced cancer patients.
    Miguel-Lillo B; Valenzuela B; Peris-Ribera JE; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):365-74. PubMed ID: 26093949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation.
    Nielsen TK; Højgaard M; Andersen JT; Poulsen HE; Lykkesfeldt J; Mikines KJ
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):343-8. PubMed ID: 25220574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.
    Krens LL; Baas JM; Verboom MC; Paintaud G; Desvignes C; Guchelaar HJ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1303-6. PubMed ID: 24705976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.
    Schaaf LJ; Dobbs BR; Edwards IR; Perrier DG
    Eur J Clin Pharmacol; 1988; 34(5):439-43. PubMed ID: 2974418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
    Alifrangis L; Schoemaker R; Skartved NJ; Hald R; Montagut C; Kopetz S; Tabernero J; Kragh M; Wade JR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):5-18. PubMed ID: 31679083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of therapeutic monoclonal antibodies.
    Dirks NL; Meibohm B
    Clin Pharmacokinet; 2010 Oct; 49(10):633-59. PubMed ID: 20818831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.
    Trang JM; LoBuglio AF; Wheeler RH; Harvey EB; Sun L; Ghrayeb J; Khazaeli MB
    Pharm Res; 1990 Jun; 7(6):587-92. PubMed ID: 2367327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
    Wilkins JJ; Vugmeyster Y; Dussault I; Girard P; Khandelwal A
    Adv Ther; 2019 Sep; 36(9):2414-2433. PubMed ID: 31278692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.